Today's Pre-Open Movers:

Immunovant (NASDAQ: IMVT) 48.9% LOWER; announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401. The Company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients in ASCEND GO-2, a Phase 2b trial in Thyroid Eye Disease (TED). Cholesterol levels were not measured in prior clinical trials of IMVT-1401 in Myasthenia Gravis (MG) and in healthy subjects. Out of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in Warm Autoimmune Hemolytic Anemia, in order to inform patients, investigators, and regulators as well as to modify the monitoring program.

Holicity Inc. (NASDAQ: HOL) 44% HIGHER; Astra, the fastest privately-funded company in history to demonstrate orbital launch capability, and Holicity Inc. (NASDAQ: HOL), a special purpose acquisition company, today announced a definitive business combination agreement that will result in Astra becoming a publicly-traded company. The transaction reflects an implied pro forma enterprise value for Astra of approximately $2.1 billion. Upon closing, the transaction is expected to provide up to $500 million in cash proceeds, including up to $300 million of cash held in the trust account of Holicity and an upsized $200 million PIPE led by funds and accounts managed by BlackRock.

GameStop Corp. (NYSE: GME) 38.9% LOWER; continues lower following the Reddit short-squeeze rally. Shares fall 31% intra-day Monday.

Prothena Corporation plc (NASDAQ: PRTA) 31.2% HIGHER; announced that following further analyses by the Company and multiple in-depth discussions with the U.S. Food and Drug Administration (FDA) regarding the previous analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study, Prothena is advancing birtamimab into the confirmatory Phase 3 AFFIRM-AL study in this category of patients with AL amyloidosis. This registration-enabling study will be conducted with a primary endpoint of all-cause mortality at p<0.10 under a Special Protocol Assessment (SPA) agreement with FDA. Birtamimab is the only investigational therapeutic that has shown a significant survival benefit in Mayo Stage IV patients with AL amyloidosis in a placebo-controlled study, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the control group in VITAL (hazard ratio (HR)=0.413, p=0.025, over 9 months). AFFIRM-AL is expected to initiate mid-2021.

AMC Entertainment Holdings, Inc. (NYSE: AMC) 28.7% LOWER; Reddit WSB stock gives up some gains.

Tiziana Life Sciences plc (Nasdaq: TLSA) 28.3% HIGHER; reports positive data from the exploratory clinical study in Brazil investigating nasally administered Foralumab, its proprietary anti-CD3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone (Dexa) in COVID-19 patients. The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil.

Koss Corporation (NASDAQ: KOSS) 24% LOWER; Reddit WSB stock gives up some gains.

TETRA Technologies Inc. (NYSE: TTI) 20.3% HIGHER; Evercore ISI upgraded from Underperform to Outperform with a price target of $3.00.

Churchill Capital Corp IV (NYSE CCIV) 11% HIGHER; continued speculation of a SPAC merger with Lucid Motors.

Virgin Galactic Holdings (NYSE: SPCE) 9.5% HIGHER; adds to intra-day move higher. Shares are up 9.5% after-hours after gaining 21.5% intra-day Monday.

Cirrus Logic, Inc. (NASDAQ: CRUS) 7.6% LOWER; reported Q3 EPS of $2.13, $0.27 better than the analyst estimate of $1.86. Revenue for the quarter came in at $485.8 million versus the consensus estimate of $460.8 million. Cirrus Logic, Inc. sees Q4 2021 revenue of $280-320 million, versus the consensus of $297.8 million.

DraftKings Inc. (NASDAQ: DKNG) 7% HIGHER; Cathie Wood's ARK takes new position.

Rambus (NASDAQ: RMBS) 6.3% LOWER; reported Q4 EPS of ($0.11), versus ($0.09) reported last year. Revenue for the quarter came in at $61.9 million, versus $59.9 million reported last year. Rambus sees Q1 2021 revenue of $60-66 million.

Revolution Medicines, Inc. (Nasdaq: RVMD) 4% LOWER; announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) 2.4% LOWER; announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock.

DXC Technology Company (NYSE: DXC) 2% LOWER; Atos SE is planning to walk away from a potential deal to buy DXC Technology (NYSE: DXC), according to Bloomberg

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Paramount Global (PARA) and Skydance are closer to a merger - CNBC
• T-Mobile (TMUS) and EQT Announce JV to Acquire Lumos